Absence of potentiation of the skin response to intradermal bradykinin by a long-acting angiotensin converting enzyme inhibitor, trandolapril, at conventional antihypertensive dosage in human volunteers: a double-blind, randomized, cross-over, placebo-controlled trial

What Was Tested

Researchers studied Bradykinin in this randomized controlled trial publication.

A double-blind, randomized, cross-over, placebo-controlled study was carried out to determine the extent and duration of potentiation of the action of bradykinin introduced intradermally by a long-acting novel angiotensin converting enzyme (ACE) inhibitor, trandolapril.

Why It Was Studied

The investigations were performed in a temperature and humidity-controlled laboratory.

Skin blood flow outside the induced weal was monitored by laser Doppler flowmetry (mean of recordings at four sites adjacent to the weal within the flare area).

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

In the crossover set-up each of the participants took both Bradykinin and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Bradykinin, Drug Synergism, Indoles, Injections, Intradermal and Regional Blood Flow.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin.

The publication is from 1992 (Postgraduate medical journal), a journal based in England.

More context: the Bradykinin compound page, all human trials.